MedDataX Logo

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

NCT ID: NCT07318155

Last Updated: 2026-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT06535568

Coronary Disease Heart Diseases Cardiovascular Diseases +22 more
RECRUITING NA

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

NCT03317002

Coronary Artery Disease
COMPLETED PHASE2

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

NCT05310968

Branch Atheromatous Disease
COMPLETED PHASE4

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

NCT00684203

Atherosclerosis Myocardial Ischemia Myocardial Infarction
COMPLETED PHASE2

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

NCT01852162

Coronary Artery Disease
COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease (CAD) Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SRSD107 dose level 1

Administered S.C.

Group Type EXPERIMENTAL

SRSD107

Intervention Type DRUG

Administered S.C.

SRSD107 dose level 2

Administered S.C.

Group Type EXPERIMENTAL

SRSD107

Intervention Type DRUG

Administered S.C.

SRSD107 dose level 3

Administered S.C.

Group Type EXPERIMENTAL

SRSD107

Intervention Type DRUG

Administered S.C.

SRSD107 dose level 4

Administered S.C.

Group Type EXPERIMENTAL

SRSD107

Intervention Type DRUG

Administered S.C.

Placebo

Administered S.C.

Group Type PLACEBO_COMPARATOR

0.9 % sodium chloride

Intervention Type DRUG

Administered S.C.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SRSD107

Administered S.C.

Intervention Type DRUG

0.9 % sodium chloride

Administered S.C.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
* Males or females aged 18 to 75 years, inclusive.
* Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive.
* History of chronic coronary and/or peripheral arterial disease

Exclusion Criteria

* Known bleeding disorder
* Severe heart failure with known left ventricular ejection fraction \<35%, or New York Heart Association (NYHA) class III or IV symptoms.
* Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.
* History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.
* Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.
* Previous use of SRSD107.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sirius Therapeutics Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SRSD107-202

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Platelet Drug Trial in Coronary Disease Progression
NCT00000496 COMPLETED PHASE3
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
NCT00291902 COMPLETED PHASE2
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
NCT00611286 COMPLETED PHASE4
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
NCT04588727 COMPLETED PHASE1
Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.
NCT03539627 COMPLETED
Vorapaxar on Thrombin Generation and Coagulability
NCT03207451 COMPLETED PHASE4
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
NCT05732701 RECRUITING NA
Aortic Arch Related Cerebral Hazard Trial (ARCH)
NCT00235248 COMPLETED PHASE3
Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study
NCT01534026 COMPLETED PHASE4
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
NCT00240643 COMPLETED PHASE2
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
NCT03568916 COMPLETED
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
NCT00000510 COMPLETED PHASE3
Subclinical Cardiovascular Disease in Psoriatic Disease
NCT03228017 COMPLETED PHASE4
Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
NCT03746782 COMPLETED
ACCEL-LOADING-ACS Study
NCT01354808 COMPLETED PHASE4
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
NCT01088503 COMPLETED
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
NCT06007222 RECRUITING PHASE4
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05638867 RECRUITING PHASE4
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
NCT04718025 UNKNOWN PHASE3
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
NCT00580216 TERMINATED PHASE3
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
NCT00133731 COMPLETED PHASE2
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
NCT04006288 COMPLETED PHASE4
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
NCT04298567 COMPLETED
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
NCT04945616 COMPLETED PHASE1
RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
NCT02288260 COMPLETED